TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Nutrition/Hygiene Education Program for the Prevention of Child Malnutrition in Rural Kenya

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Child of a mother living in the catchment area of the study who delivered during the enrollment period

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 6 Months
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): nutrition and hygiene education by community health workers

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Response to Social Rejection in Suicidal Behavior

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Non specifics~* Female~* Between 18 and 65 years~* Main diagnosis of unipolar major depressive episode (DSM-IV criteria)~* Having signed informed consent~* Able to understand nature, aims, and methodology oh the study~* Specifics :~* Having a personal history of suicidal behavior (group : depressed patient with history of SB) OR~* Not Having personal history of suicidal behavior (group : depressed patient without history of SB)~Exclusion criteria:~* Inflammatory or intercurrent pathology~* Lifetime history of schizophrenia, or schizoaffective or bipolar disorder, according to DSM-IV criteria;~* Current diagnosis of substance abuse or dependence in the last year (excluding tobacco)~* Current organic mental disorder or mental retardation, or severe comorbid medical condition~* Participation in another clinical trial~* Pregnancy~* Not able to speak, read and understand French~* Patient on protective measures (guardianship or trusteeship)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Depressive patients (Type: OTHER): Depressive patients with or without story of suicidal behavior will pass the TSST and will have a psychological assessment to complete with a questionnaire on their smartphone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ABCB5 as a Prognostic Marker in Survival of Cultivated Limbal Stem Cell Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Bilateral limbal stem cell deficiency of any etiology.~2. Corneal impression cytology positive for goblet cells.~3. Ocular ultrasound results within normal parameters.~4. Agree to participate in the study and sign the informed consent.~Exclusion Criteria:~1. Active immunological diseases.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stem Cell Transplantation (Type: EXPERIMENTAL): Cultivated Limbal Stem Cell Transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Response to Phenylketonuria to Tetrahydrobiopterin (BH4)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject and/or parent or guardian must be capable of understanding and providing written informed consent~* Subjects must have Phenylketonuria (PKU)or hyperphenylalaninemia (HPA), defined as baseline blood Phe levels of \>600 umol/L~* Subjects must be at least 10 years of age, and may be of either gender and any ethnic group~* Female subjects of childbearing potential must agree to use adequate birth control or refrain from sexual activity throughout study participation~Exclusion Criteria:~* Female subjects who are pregnant or breastfeeding~* Subjects who have concurrent diseases or conditions that require medication or treatment~* Subjects who require concomitant treatment with any drug known to inhibit folate synthesis~* Subjects who have been treated with any investigational drug within 30 days

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Drug: tetrahydrobiopterin (BH4) Either placebo or BH4, 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
- Control Arm (Type: PLACEBO_COMPARATOR): Drug: tetrahydrobiopterin (BH4) Either placebo or BH4, 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of High Doses Penicillin V Versus High Doses Amoxicillin in the Treatment of Non-severe Pneumonia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years to 75 years (inclusive).~* Signs and symptoms of lower respiratory tract infection.~* Radiological confirmation of the diagnosis of pneumonia or not radiological confirmation but the patient has the following symptoms: high fever (\> 38.5 ° C), cough and purulent sputum and auscultation of crackles in a pulmonary focus, the researcher undertakes to confirm after inclusion pneumonia with mandatory radiological study.~* Signature of informed consent.~Exclusion Criteria:~* Impaired consciousness: confused state, delirium, drowsiness, stupor or coma, at the discretion of the investigator~* Respiratory rate\> 30 breaths / minute~* Heart rate\> 125 beats / minute~* Systolic blood pressure \<90 mm ??Hg or diastolic BP \<60 mm Hg~* Hypersensitivity to beta-Lactamics~* O2 saturation \<92%~* Axillary temperature\> 40 ° C~* bronchial Asthma~* Pregnancy or lactation~* Significant comorbidities: renal failure, liver cirrhosis, heart failure, chronic obstructive pulmonary disease, ischemic heart disease diagnosed less than 6 months, stroke diagnosed less than 6 months ago and / or type 1 diabetes mellitus~* Significant alteration in chest radiography: alveolar infiltrates in more than one lobe or bilateral pleural effusion or pulmonary cavitation~* Problems to meet the treatment at home: sociopathy or psychiatric problems, drug and alcohol addiction, or, an unsuitable family environment~* Lack of tolerance to oral therapy: presence of nausea and vomiting, gastrectomy, post-surgery or frank diarrhea~* Immunosuppression: chronic HIV infection, transplant, neutropenic, or, patients receiving immunosuppressive therapy~* active malignancy~* terminal disease~* Hospitalization in the last month~* Taking any systemic antibiotic in the previous three days or a full use of oral antibiotics prior to inclusion in the previous two weeks (use of urinary antiseptics is not a reason for exclusion).~* Difficulty to attend follow-up visits~* Refusal to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Penicillin V (Type: EXPERIMENTAL): Penicillin V, 1600000 IU every 8h during 10 days.
- Amoxicillin (Type: ACTIVE_COMPARATOR): Amoxicillin, 1 g every 8h during 10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* female patients, 18-65 years of age;~* locally recurrent and metastatic breast cancer;~* measurable or evaluable disease;~* ECOG performance status of 0-2;~* LVEF \>=50% without clinical symptoms or signs of heart failure.~Exclusion Criteria:~* unknown HER2 status, or known HER2-positive status;~* prior chemotherapy for locally recurrent or metastatic disease;~* prior adjuvant or neoadjuvant taxane therapy within 12 months prior to start of treatment;~* clinical or radiological evidence of CNS metastases;~* clinically significant cardiovascular disease.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Completed 26 weeks of double-blind phase of Study ONO-4641POU006~Exclusion Criteria:~* Presence of any dermatological abnormalities during Study ONO-4641POU006 that could increase the risk of the patient developing a skin cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- ONO-4641 0.15 milligram (mg) - 0.15 mg (Type: EXPERIMENTAL): None
- ONO-4641 0.10 mg - 0.10 mg (Type: EXPERIMENTAL): None
- ONO-4641 0.05 mg - 0.05 mg (Type: EXPERIMENTAL): None
- Placebo - ONO4641 0.15 mg (Type: EXPERIMENTAL): None
- Placebo - ONO4641 0.10 mg (Type: EXPERIMENTAL): None
- Placebo - ONO4641 0.05 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Nutritional Intervention Program in Malnourished Patients Admitted for Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients admitted for heart failure~* \> 18 years old~* Malnutrition determined by MNA test (\< 17 points)~Exclusion Criteria:~* If is not possible to perform a nutritional assessment~* Planned PCI or CABG to correct heart failure etiology

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nutritional intervention (Type: ACTIVE_COMPARATOR): It will last 6 months. Will be conducted by a physician nutrition specialist assisted by a technician in diet and nutrition. The first visit will take place during admission. The patient receives dietary advice and a customized diet designed to optimize energy intake and macro/micro-nutrients needs.
- Care as usual (Type: PLACEBO_COMPARATOR): The patients are referred to their cardiologyst and primary care physicians

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cardiovascular Disease Screening

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* ELIGIBILITY CRITERIA:~No one will be excluded from this study based on race, gender, or ethnicity.~A. General Inclusion Criteria:~* Age greater than or equal to 18~* Capable of giving informed consent.~B. General Exclusion Criteria:~* Pregnant women (uncertain patients will have urine or blood testing).~* Decompensated heart failure (unable to lie flat in bed).~Test Specific Exclusion Criteria:~A. CT Exclusion Criteria (excludes contrast enhanced CT scan only):~* Allergy to iodinated contrast agent excludes contrast enhanced CT research studies.~* Multiple myeloma.~* Patients with severe kidney disease (eGFR less than 30 mL/min/1.73 m(2).~B. Beta Antagonist Exclusions (excluded the use of beta blocker only):~* Asthma or severe chronic lung disease/emphysema with regular use of inhaler.~* Decompensated heart failure.~C. MRI Exclusion Criteria (excludes MRI scan only):~* Cardiac pacemaker or implantable defibrillator.~* Cerebral aneurysm clip.~* Neural stimulator (e.g. TENS-Unit).~* Any type of ear implant.~* Metal in eye (e.g. from machining).~* Any implanted device (e.g. insulin pump, drug infusion device).~D. Exclusions from MRI contrast agents:~* Lactating women unless they are willing to discard breast milk for 24 hours.~* Severe kidney disease (less than 30 mL/min/1.73 m(2).~E. Vasodilator Exclusions (excludes some vasodilator stress testing):~* Asthma or chronic obstructive pulmonary disease (emphysema) actively treated with bronchodilators or leukotriene receptor antagonists (albuterol, seravent, atrovent, montelukast singulair, zafirlukast Accolate. These conditions only exclude adenosine and dipyridamole.~* Second degree (Type II) and third degree atrioventricular heart block.~F. Exclusions from Dobutamine stress MRI only:~* Severe problems with heart rhythms.~* Severe high blood pressure.~G. Exclusion criteria for atropine (given during dobutamine stress echocardiography when target heart rate not achievable with dobutamine alone).~* Narrow angle glaucoma.~* Known or suspected severe bladder outlet obstruction due to prostatic hypertrophy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with known or suspected cardiovascular disease (Type: None): Patients referred to protocol with known or suspected cardiovascular disease for further evaluation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Confirmed or highly-likely diagnosis of one of the eight UCDs as established for the Longitudinal Study (5101) (See section 4.2 Inclusion Criteria, Table 4 for diagnostic criteria for patients with UCD)~* Enrolled in Longitudinal Study of Urea Cycle Disorders (RDCRN UCDC #5101)~Exclusion Criteria:~* UCD patients who have undergone orthotopic liver transplantation~* Significant chronic medical co-morbidity that might confound the analysis as determined by the site investigators.~* Significant co-morbidities include but are not limited to:~  * diabetes, liver failure + cirrhosis~ * renal failure~ * cardiac disease~ * chronic inflammatory diseases~ * asthma requiring daily long-term control medications~ * significant respiratory disease.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: In-vivo Wear Behaviour of AS Coated Versus Uncoated Columbus® Total Knee Prosthesis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Indication for a primary bicondylar total knee endoprosthesis with the Columbus® DD knee prosthesis~* Written signed informed consent of patient~* Willingness and mental ability to participate at the long-term follow-up examinations~Exclusion Criteria:~* Pregnancy~* Patient age \<45 and \>75years~* Acute inflammatory arthritis~* Coagulation disorders (e.g. Haemophilia)

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Columbus® DD Primary CoCr (Type: None): Columbus® Deep Dish (DD) Primary Cobalt Chromium (CoCr)
- Columbus® DD Primary CoCr AS coated (Type: None): Columbus® Deep Dish (DD) Primary Cobalt Chromium (CoCr) Advanced Surface

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-Idiopathic Scoliosis Treated With Tranexamic Acid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Children with secondary scoliosis undergoing posterior spinal fusion~Exclusion Criteria:~1. Known bleeding disorder as this may increase the risk of bleeding~2. Current antifibrinolytic therapy as these patients may bleed less~3. Patient or family history of thromboembolic disease as there may be potential risk of thrombosis~4. Use of NSAIDS within 5 days of surgery as this may increase the risk of bleeding~5. Known allergy to TXA~6. History of renal insufficiency as TXA is renally excreted~7. Colour vision disturbance

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- . Tranexamic acid low dose 10 mg/kg (Type: EXPERIMENTAL): None
- Tranexamic acid 100mg/kg (Type: EXPERIMENTAL): None
- Saline Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study of OTO-104 in Subjects With Meniere's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria includes, but is not limited to:~* Subject has a diagnosis of definite unilateral Meniere's disease.~* Subject agrees to maintain their current standard of care treatments for Meniere's disease while on-study.~Exclusion Criteria includes, but is not limited to:~* Subject has an infection in the ear, sinuses, or upper respiratory system.~* Subject is pregnant or lactating.~* Subject has a history of immunodeficiency disease.~* Subject has active or recent (\<1 month prior to screening) middle ear disease, including but not limited to: chronic otitis media, acute otitis media, middle ear effusions, middle ear atelectasis, or cholesteatoma.~* Subject has experienced an adverse reaction to intratympanic injection of steroids.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- OTO-104 (Type: EXPERIMENTAL): 12 mg dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Pupillometry for cyp2d6 Phenotyping in Children Treated With Tramadol

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria~* Age 1-15 year at time of inclusion~* Weight ≥ 10 kg~* Treatment with tramadol as a pain killer administrated as part of their routine care~* Parent/Legal guardian has been informed about the study and has signed Informed Consent Form~Exclusion criteria~* Known kidney or liver disease~* Concomitant treatment with inhibitors/inducers of CYP2D6 and CYP3A~* Documented previous adverse reaction to tramadol or dextromethorphan~* Concomitant treatment with any opiate drug and/or any drug with a known impact on pupil size~* Any concomitant condition, which in the opinion of the investigator would preclude a subject's participation in the study

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- single arm study (Type: EXPERIMENTAL): pupillometry, CYP2D6 genotyping and phenotyping

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues